疾病专题报告(四):双抗在自免领域潜力大

财通证券
Nov 11

自免双抗领域已有真实世界临床数据验证,双抗技术平台差异度小,重点关注靶点选择及临床前优化:在真实世界中开展的多项ⅡT 研究已证明TCE 可通过B 细胞清除的策略使自免患者缓解,而基于免疫通路的双抗已有部分临床数据表明其有效性,因此自免疾病中双抗的开发正处于方兴未艾的阶段。另外,通过对目前药企披露的双抗技术平台对比,我们认为平台差异度小,重点关注企业研发时双抗靶点的选择及临床前优化工作,这将成为决定...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10